Compare Hasbro, Inc. (HAS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs GeneDx Holdings Corp — how do they compare? Hasbro, Inc. trades at $93.8 (market cap $13.05B), while GeneDx Holdings Corp trades at $67.95 (market cap $2.02B). The key difference: Hasbro, Inc. is far larger — about 6.5× GeneDx Holdings Corp's market cap, and Hasbro, Inc. pays a 3.03% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and GeneDx Holdings Corp for 19 Days on average.
| HAS | WGS | |
|---|---|---|
Market Cap | $13.05B | $2.02B |
Volume | 1,207,655 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $167.51 |
52-Week Low | $70.95 | $34.51 |
Typical Hold Time | 97 Days | 19 Days |
Enterprise Value | $15.24B | $2.05B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.22, up 3.82% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical stance with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 64.41% gross margins and impressive ROE of 167.83%, despite a net loss in 2025. Analyst consensus remains positive with 51.52% buy ratings and a $107.60 price target, representing 14% upside potential from current levels.
Investment outlook appears favorable with strong gaming segment growth and cost-saving initiatives driving projected 2026 net income of $794 million. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The upcoming Q3 2026 earnings report on October 20 will be crucial for validating the company's turnaround trajectory and growth projections.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
